Adma Biologics (ADMA) Common Equity (2011 - 2026)
Adma Biologics' (ADMA) quarterly Common Equity came in at $477.3 million in Q4 2025, up 36.76% YoY from $349.0 million in Q4 2024, and up 10.7% on a QoQ basis from $431.2 million in Q3 2025.
Adma Biologics (ADMA) Common Equity (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 15 years of Common Equity data on file, last reported at $477.3 million in Q4 2025.
- Quarterly Common Equity rose 36.76% year-over-year to $477.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $477.3 million (up 36.76% YoY) and the FY2025 annual result came in at $477.3 million, up 36.76% from the prior year.
- Common Equity advanced to $477.3 million in Q4 2025, from $431.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $477.3 million in Q4 2025 to a low of $100.4 million in Q3 2022.
- A 5-year average of $207.2 million and a median of $149.1 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity declined 11.03% — and 2024, when it soared 158.14%.
- Tracing ADMA's Common Equity over 5 years: stood at $141.2 million in 2021, then rose by 7.65% to $152.0 million in 2022, then retreated by 11.03% to $135.2 million in 2023, then soared by 158.14% to $349.0 million in 2024, then jumped by 36.76% to $477.3 million in 2025.
- The last three Common Equity figures came in at $477.3 million (Q4 2025), $431.2 million (Q3 2025), and $398.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 408.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 408.21 Mn |
| Dec 31, 2025 | 477.32 Mn |
| Sep 30, 2025 | 431.19 Mn |
| Jun 30, 2025 | 398.33 Mn |
| Mar 31, 2025 | 373.42 Mn |
| Dec 31, 2024 | 349.02 Mn |
| Sep 30, 2024 | 231.89 Mn |
| Jun 30, 2024 | 188.27 Mn |
| Mar 31, 2024 | 153.71 Mn |
| Dec 31, 2023 | 135.21 Mn |
| Sep 30, 2023 | 151.44 Mn |
| Jun 30, 2023 | 146.76 Mn |
| Mar 31, 2023 | 145.66 Mn |
| Dec 31, 2022 | 151.97 Mn |
| Sep 30, 2022 | 100.38 Mn |
| Jun 30, 2022 | 114.40 Mn |
| Mar 31, 2022 | 126.93 Mn |
| Dec 31, 2021 | 141.17 Mn |
| Sep 30, 2021 | 102.78 Mn |
| Jun 30, 2021 | 111.59 Mn |